Literature DB >> 3829300

Barbiturates inhibit stress-induced analgesia.

I Kissin, J O Mason, H R Vinik, J McDanal, E L Bradley.   

Abstract

The effect of pentobarbitone and thiopentone on stress-induced analgesia was studied in 40 male Sprague-Dawley rats. Antinociception was determined by measuring motor reaction threshold to the noxious pressure on the tail with the use of an "Analgesymeter." Stress was induced by placement of a clamp on the hind paw. The stress procedure was found to cause an increase in reaction threshold, which was partially suppressed by naloxone 0.5 mg X kg-1. Pentobarbitone in a subanaesthetic dose of 25 mg X kg-1, SC, almost completely abolished the stress-induced increase in the reaction threshold (an increase in reaction threshold from 329 +/- 33 g to 486 +/- 62 g in control group, and from 250 +/- 26 g to 273 +/- 35 g in pentobarbitone group, p less than 0.02 for the difference in the threshold changes). Thiopentone used in a dose of 25 mg X kg-1, IV, caused a loss of the righting reflex for 37 +/- 10 minutes; stress procedure applied ten minutes after regaining the righting reflex did not cause any increase in the reaction threshold (with an increase in the reaction threshold in control group from 355 +/- 50 g to 540 +/- 26 g, p less than 0.001 for the difference between the groups). The results suggest that the barbiturates in subanaesthetic doses inhibit stress-induced analgesia. Thiopentone used in an anaesthetic dose has the potential for inhibition of stress-induced analgesia in the period of recovery from anaesthesia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3829300     DOI: 10.1007/BF03015332

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  19 in total

1.  DIFFERENTIATION OF TWO TYPES OF PAIN BY ANESTHETICS.

Authors:  J G ROBSON; H T DAVENPORT; R SUGIYAMA
Journal:  Anesthesiology       Date:  1965 Jan-Feb       Impact factor: 7.892

2.  Alterations in response to somatic pain associated with anaesthesia. II. The effect of thiopentone and pentobarbitone.

Authors:  J W DUNDEE
Journal:  Br J Anaesth       Date:  1960-09       Impact factor: 9.166

3.  Some pain threshold studies with particular reference to thiopentone.

Authors:  J CLUTTON-BROCK
Journal:  Anaesthesia       Date:  1960-01       Impact factor: 6.955

4.  The measurement of pain; prototype for the quantitative study of subjective responses.

Authors:  H K BEECHER
Journal:  Pharmacol Rev       Date:  1957-03       Impact factor: 25.468

5.  A classification of opiate receptors that mediate antinociception in animals.

Authors:  M B Tyers
Journal:  Br J Pharmacol       Date:  1980-07       Impact factor: 8.739

6.  Influence of subnarcotic doses of Althesin (CT1341) on pain induced by two types of pain stimulus.

Authors:  M Morgan; J G Whitwam; P Page
Journal:  Br J Anaesth       Date:  1973-05       Impact factor: 9.166

7.  In vivo studies on spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a differential association of mu, delta and kappa receptors with visceral chemical and cutaneous thermal stimuli in the rat.

Authors:  C Schmauss; T L Yaksh
Journal:  J Pharmacol Exp Ther       Date:  1984-01       Impact factor: 4.030

8.  Neurophysiology of pain and pain modulation.

Authors:  H L Fields
Journal:  Am J Med       Date:  1984-09-10       Impact factor: 4.965

9.  Halothane antagonizes effect of morphine on the motor reaction threshold in rats.

Authors:  I Kissin; J A Jebeles
Journal:  Anesthesiology       Date:  1984-12       Impact factor: 7.892

10.  Pain modulation by 5-hydroxytryptaminergic agents and morphine as measured by three pain tests.

Authors:  S G Dennis; R Melzack
Journal:  Exp Neurol       Date:  1980-08       Impact factor: 5.330

View more
  1 in total

1.  Hyperalgesia during sedation: effects of barbiturates and propofol in the rat.

Authors:  A Ewen; D P Archer; N Samanani; S H Roth
Journal:  Can J Anaesth       Date:  1995-06       Impact factor: 5.063

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.